ONLINE FIRST
The efficacy of anti-tumor necrosis factor therapies in rheumatoid arthritis has been demonstrated in randomized clinical trials. The purpose of the present study was to evaluate the effectiveness of these agents for the treatment of rheumatoid arthritis in a real-world setting...
FULL TEXT
Anna D'Souza, PhD; Brian L. Meissner, PharmD, PhD; Boxiong Tang, MD, PhD; R. Scott McKenzie, MD; Catherine T. Piech, MBA
Stakeholder Perspective by Matthew Mitchell, PharmD, MBA
COMMENTARY
It is impossible to overstate the extraordinary range and complexity of the newly enacted health reform law...
FULL TEXT
Kip Piper, MA, FACHE

Payment reform has moved to the forefront of the conversation...
FULL TEXT
Jim Evans
I could not help noticing that the study “Healthcare Costs Associated with Switching from Brand to Generic Levothyroxine†was funded by Abbott...
FULL TEXT
Kevin Slavik, RPh, MHA
FEATURES
BPD affects more than 2.3 million adult Americans, or 1% of the population, by conservative estimates...
FULL TEXT
Jeff J. Guo, PhD; Nick C. Patel, PharmD, PhD; Hong Li, PhD; Paul E. Keck Jr, MD
Stakeholder Perspective by Nirav R. Shah, MD, MPH
The purpose of the Work Loss and Productivity study was to quantify the impact of etanercept therapy among employees with rheumatoid arthritis...
FULL TEXT
Denise Globe, PhD; Peter Mazonson, MD, MBA; Chris Santas, MBA; Regina Murphy, MBA; Annie Cheng; Xingyue Huang, BPharm, PhD; Arthur Kavanaugh, MD
Stakeholder Perspective by Atheer A. Kaddis, PharmD
Pharmaceutical manufacturers face an increasing drug utilization dilemma...
FULL TEXT
F. Randy Vogenberg, RPh, PhD
Stakeholder Perspective by Gary M. Owens, MD
GENERIC DRUG TRENDS
Strategies such as these result in a reduction of overall pharmacy costs and a change in plan member behavior...
FULL TEXT
Anthony F. Liu, MSCS; Tom Jecklin; Geoffrey Lee; James Hogan
MEETING HIGHLIGHTS
AMCP

Costs resulting from nonadherence have been estimated to exceed a staggering $100 billion annually...
FULL TEXT
Joshua N. Liberman, PhD; Janice Moore, MPH; Asif Ally, RPh, MBA; Troyen A. Brennan, JD, MD
DDW
American Society of Hypertension
DRUG PIPELINE